Clinical Trial Update: Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

View source ↗

Summary

A completed clinical trial update reporting the real-world outcomes of first-line nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Opdivo (nivolumab) (nivolumab)
• Yervoy (Ipilimumab) (Ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer | Status: COMPLETED